<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Innoviva, Inc. — News on 6ix</title>
<link>https://6ix.com/company/innoviva-inc</link>
<description>Latest news and press releases for Innoviva, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 06 May 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/innoviva-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835842d78dffbe2df0fcffa.webp</url>
<title>Innoviva, Inc.</title>
<link>https://6ix.com/company/innoviva-inc</link>
</image>
<item>
<title>Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress</title>
<link>https://6ix.com/company/innoviva-inc/news/innoviva-reports-first-quarter-2026-financial-results-highlights-recent-company-progress</link>
<guid isPermaLink="true">https://6ix.com/company/innoviva-inc/news/innoviva-reports-first-quarter-2026-financial-results-highlights-recent-company-progress</guid>
<pubDate>Wed, 06 May 2026 20:05:00 GMT</pubDate>
<description>BURLINGAME, Calif., May 06, 2026--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the first quarter ended March 31, 2026, and highlighted select corporate progress and achievements.</description>
</item>
<item>
<title>Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation’s 2026 Antimicrobial Resistance Benchmark Report</title>
<link>https://6ix.com/company/innoviva-inc/news/innoviva-specialty-therapeutics-earns-strong-performance-rating-in-access-to-medicine-foundations-2026-antimicrobial-resistance-benchmark-report</link>
<guid isPermaLink="true">https://6ix.com/company/innoviva-inc/news/innoviva-specialty-therapeutics-earns-strong-performance-rating-in-access-to-medicine-foundations-2026-antimicrobial-resistance-benchmark-report</guid>
<pubDate>Tue, 10 Mar 2026 10:30:00 GMT</pubDate>
<description>WALTHAM, Mass., March 10, 2026--Innoviva Specialty Therapeutics, a subsidiary of Innoviva Inc., today announced that its infectious disease therapeutic portfolio earned a strong performance rating of 80% in the 2026 Antimicrobial Resistance (AMR) Benchmark Report published by the Access to Medicine Foundation. The score represents the highest rating in the small- and medium-sized enterprise (SME) category, achieved by only one other company in this year’s report. The AMR Benchmark evaluates phar</description>
</item>
<item>
<title>Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress</title>
<link>https://6ix.com/company/innoviva-inc/news/innoviva-reports-fourth-quarter-and-full-year-2025-financial-results-highlights-recent-company-progress</link>
<guid isPermaLink="true">https://6ix.com/company/innoviva-inc/news/innoviva-reports-fourth-quarter-and-full-year-2025-financial-results-highlights-recent-company-progress</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>Durable royalties portfolio generated $58.4 million in revenue for the fourth quarter and $250.3 million for the full year IST achieved U.S. net product</description>
</item>
<item>
<title>Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference</title>
<link>https://6ix.com/company/innoviva-inc/news/innoviva-to-participate-in-the-oppenheimer-36th-annual-healthcare-life-sciences-conference</link>
<guid isPermaLink="true">https://6ix.com/company/innoviva-inc/news/innoviva-to-participate-in-the-oppenheimer-36th-annual-healthcare-life-sciences-conference</guid>
<pubDate>Thu, 19 Feb 2026 13:00:00 GMT</pubDate>
<description>BURLINGAME, Calif., February 19, 2026--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at</description>
</item>
<item>
<title>U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents</title>
<link>https://6ix.com/company/innoviva-inc/news/us-fda-approves-nuzolvencer-zoliflodacin-first-class-single-dose-oral-antibiotic</link>
<guid isPermaLink="true">https://6ix.com/company/innoviva-inc/news/us-fda-approves-nuzolvencer-zoliflodacin-first-class-single-dose-oral-antibiotic</guid>
<pubDate>Fri, 12 Dec 2025 05:00:00 GMT</pubDate>
<description>FDA approval was based on results from the largest Phase 3 clinical trial ever conducted for a new treatment against Neisseria gonorrhoeae infection in</description>
</item>
<item>
<title>Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea</title>
<link>https://6ix.com/company/innoviva-inc/news/innoviva-specialty-therapeutics-announces-publication-lancet-positive-zoliflodacin</link>
<guid isPermaLink="true">https://6ix.com/company/innoviva-inc/news/innoviva-specialty-therapeutics-announces-publication-lancet-positive-zoliflodacin</guid>
<pubDate>Thu, 11 Dec 2025 05:00:00 GMT</pubDate>
<description>Phase 3 findings show oral zoliflodacin to be non-inferior to the combination of ceftriaxone and azithromycin for the treatment of uncomplicated urogenital</description>
</item>
<item>
<title>Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference</title>
<link>https://6ix.com/company/innoviva-inc/news/innoviva-participate-37th-annual-piper-sandler-healthcare-conference-2025-11-25</link>
<guid isPermaLink="true">https://6ix.com/company/innoviva-inc/news/innoviva-participate-37th-annual-piper-sandler-healthcare-conference-2025-11-25</guid>
<pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
<description>BURLINGAME, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties</description>
</item>
<item>
<title>Beacon Biosignals Raises $86M to Accelerate AI-Driven Insights into Brain Health</title>
<link>https://6ix.com/company/innoviva-inc/news/beacon-biosignals-raises-dollar86m-to-accelerate-ai-driven-insights-into-brain-health</link>
<guid isPermaLink="true">https://6ix.com/company/innoviva-inc/news/beacon-biosignals-raises-dollar86m-to-accelerate-ai-driven-insights-into-brain-health</guid>
<pubDate>Thu, 13 Nov 2025 11:30:00 GMT</pubDate>
<description>New funding will expand Beacon’s precision medicine data platform, unlocking discoveries and treatments for neurological and psychiatric diseaseBOSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Beacon Biosignals, a leading neurotechnology company powering AI-driven diagnostics and precision medicines for the brain, today announced an oversubscribed $86 million Series B to build the world’s largest neurodiagnostic dataset and advance the clinical application of AI-driven biomarkers for brain health. The</description>
</item>
<item>
<title>Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress</title>
<link>https://6ix.com/company/innoviva-inc/news/innoviva-reports-third-quarter-2025-financial-results-highlights-recent-company</link>
<guid isPermaLink="true">https://6ix.com/company/innoviva-inc/news/innoviva-reports-third-quarter-2025-financial-results-highlights-recent-company</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>Generated $63.4 million in revenue from durable royalties portfolio IST achieved U.S. net product sales of $29.9 million, representing 52% year-over-year</description>
</item>
<item>
<title>Antheia Appoints Eric d'Esparbes as Chief Financial Officer</title>
<link>https://6ix.com/company/innoviva-inc/news/antheia-appoints-eric-desparbes-as-chief-financial-officer</link>
<guid isPermaLink="true">https://6ix.com/company/innoviva-inc/news/antheia-appoints-eric-desparbes-as-chief-financial-officer</guid>
<pubDate>Tue, 21 Oct 2025 12:00:00 GMT</pubDate>
<description>Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, today announced the appointment of Eric d'Esparbes as Chief Financial Officer. d'Esparbes will oversee Antheia's financial strategy and operations as the company advances its next phase of commercialization and unlocks its U.S. manufacturing capabilities. His appointment comes at a critical point in Antheia's trajectory, following the company's $56 million Series C fundraise in June of this year an</description>
</item>
<item>
<title>Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025</title>
<link>https://6ix.com/company/innoviva-inc/news/innoviva-specialty-therapeutics-announces-oral-presentation-featuring-new-analyses</link>
<guid isPermaLink="true">https://6ix.com/company/innoviva-inc/news/innoviva-specialty-therapeutics-announces-oral-presentation-featuring-new-analyses</guid>
<pubDate>Mon, 20 Oct 2025 04:00:00 GMT</pubDate>
<description>Zoliflodacin, an investigational single-dose oral antibiotic for uncomplicated gonorrhea, to be featured in oral presentation with key subset analyses from</description>
</item>
<item>
<title>Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025</title>
<link>https://6ix.com/company/innoviva-inc/news/innoviva-specialty-therapeutics-deliver-six-presentations-its-infectious-diseases-and</link>
<guid isPermaLink="true">https://6ix.com/company/innoviva-inc/news/innoviva-specialty-therapeutics-deliver-six-presentations-its-infectious-diseases-and</guid>
<pubDate>Tue, 07 Oct 2025 04:00:00 GMT</pubDate>
<description>Highlights include an oral presentation of a subset analysis from the Phase 3 clinical trial of zoliflodacin, an investigational single-dose oral treatment</description>
</item>
<item>
<title>Innoviva to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/innoviva-inc/news/innoviva-participate-upcoming-investor-conferences-2025-08-26</link>
<guid isPermaLink="true">https://6ix.com/company/innoviva-inc/news/innoviva-participate-upcoming-investor-conferences-2025-08-26</guid>
<pubDate>Tue, 26 Aug 2025 04:00:00 GMT</pubDate>
<description>BURLINGAME, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties</description>
</item>
<item>
<title>Innoviva Specialty Therapeutics’ Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award</title>
<link>https://6ix.com/company/innoviva-inc/news/innoviva-specialty-therapeutics-antimicrobial-therapies-zevterar-and-xacduror</link>
<guid isPermaLink="true">https://6ix.com/company/innoviva-inc/news/innoviva-specialty-therapeutics-antimicrobial-therapies-zevterar-and-xacduror</guid>
<pubDate>Wed, 13 Aug 2025 04:00:00 GMT</pubDate>
<description>WALTHAM, Mass.--(BUSINESS WIRE)-- Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today that two of the company’s</description>
</item>
<item>
<title>Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update</title>
<link>https://6ix.com/company/innoviva-inc/news/armata-pharmaceuticals-announces-second-quarter-2025-results-and-provides-corporate-update-1</link>
<guid isPermaLink="true">https://6ix.com/company/innoviva-inc/news/armata-pharmaceuticals-announces-second-quarter-2025-results-and-provides-corporate-update-1</guid>
<pubDate>Tue, 12 Aug 2025 20:05:00 GMT</pubDate>
<description>Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter ended June 30, 2025, and provided a corporate update.</description>
</item>
<item>
<title>Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress</title>
<link>https://6ix.com/company/innoviva-inc/news/innoviva-reports-second-quarter-2025-200500824</link>
<guid isPermaLink="true">https://6ix.com/company/innoviva-inc/news/innoviva-reports-second-quarter-2025-200500824</guid>
<pubDate>Wed, 06 Aug 2025 20:05:00 GMT</pubDate>
<description>BURLINGAME, Calif., August 06, 2025--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the second quarter ended June 30, 2025, and highlighted select corporate progress and achievements.</description>
</item>
<item>
<title>FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025</title>
<link>https://6ix.com/company/innoviva-inc/news/fda-grants-priority-review-zoliflodacin-new-drug-application-treatment-uncomplicated</link>
<guid isPermaLink="true">https://6ix.com/company/innoviva-inc/news/fda-grants-priority-review-zoliflodacin-new-drug-application-treatment-uncomplicated</guid>
<pubDate>Thu, 12 Jun 2025 04:00:00 GMT</pubDate>
<description>FDA is expected to notify Innoviva Specialty Therapeutics regarding its decision to conduct an Advisory Committee Meeting in the Day 74 letter If approved,</description>
</item>
<item>
<title>Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults</title>
<link>https://6ix.com/company/innoviva-inc/news/innoviva-specialty-therapeutics-receives-fda-new-drug-application-acceptance</link>
<guid isPermaLink="true">https://6ix.com/company/innoviva-inc/news/innoviva-specialty-therapeutics-receives-fda-new-drug-application-acceptance</guid>
<pubDate>Tue, 10 Jun 2025 04:00:00 GMT</pubDate>
<description>In laboratory studies, zoliflodacin has been shown to be active against Neisseria gonorrhoeae including multidrug-resistant strains. If approved,</description>
</item>
<item>
<title>ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections</title>
<link>https://6ix.com/company/innoviva-inc/news/zevterar-ceftobiprole-advanced-generation-cephalosporin-antibiotic-now-commercially</link>
<guid isPermaLink="true">https://6ix.com/company/innoviva-inc/news/zevterar-ceftobiprole-advanced-generation-cephalosporin-antibiotic-now-commercially</guid>
<pubDate>Tue, 20 May 2025 04:00:00 GMT</pubDate>
<description>ZEVTERA is the first and only U.S. Food and Drug Administration-approved cephalosporin indicated to treat Staphylococcus aureus bacteremia (SAB), including</description>
</item>
<item>
<title>Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress</title>
<link>https://6ix.com/company/innoviva-inc/news/innoviva-reports-first-quarter-2025-financial-results-highlights-recent-company</link>
<guid isPermaLink="true">https://6ix.com/company/innoviva-inc/news/innoviva-reports-first-quarter-2025-financial-results-highlights-recent-company</guid>
<pubDate>Wed, 07 May 2025 04:00:00 GMT</pubDate>
<description>Core royalty platform maintained strong performance, generating $61.3 million in revenue Innoviva Specialty Therapeutics achieved U.S. net product sales of</description>
</item>
</channel>
</rss>